Get access
Clinical & Experimental Allergy

Prenatal exposure to acid-suppressive drugs and the risk of allergic diseases in the offspring: a cohort study

Authors

  • B. Mulder,

    Corresponding author
    1. Department of PharmacoEpidemiology & PharmacoEconomics, University Centre of Pharmacy, University of Groningen, Groningen, The Netherlands
    • Correspondence:

      Bianca Mulder, Research fellow, Department of PharmacoEpidemiology & PharmacoEconomics,

      University Centre of Pharmacy, University of Groningen, P.O. Box XB45, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands.

      E-mail: B.Mulder@rug.nl

    Search for more papers by this author
  • C. C. M. Schuiling-Veninga,

    1. Department of PharmacoEpidemiology & PharmacoEconomics, University Centre of Pharmacy, University of Groningen, Groningen, The Netherlands
    Search for more papers by this author
  • H. J. Bos,

    1. Department of PharmacoEpidemiology & PharmacoEconomics, University Centre of Pharmacy, University of Groningen, Groningen, The Netherlands
    Search for more papers by this author
  • T. W. De Vries,

    1. Department of Pediatrics, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
    Search for more papers by this author
  • S. S. Jick,

    1. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA
    2. Boston Collaborative Drug Surveillance Program, Boston, MA, USA
    Search for more papers by this author
  • E. Hak

    1. Department of PharmacoEpidemiology & PharmacoEconomics, University Centre of Pharmacy, University of Groningen, Groningen, The Netherlands
    2. Department of Epidemiology, University Medical Centre Groningen, Groningen, The Netherlands
    Search for more papers by this author

Summary

Background

Recent studies reported increased risks for the development of asthma in children after prenatal exposure to acid-suppressive drugs. As a result of common pathogenesis, associations could also be present for other allergic diseases.

Methods

Using the prescription database IADB.nl, we conducted a cohort study amongst 33 536 children in the Netherlands, with a maximum follow-up of 8 years. Maternal exposure was defined as ≥1 dispensed prescription for proton pump inhibitors (PPIs) and/or Histamine 2-antagonists (H2As) during pregnancy. Children were considered to have a drug-treated allergic disease if they received either ≥2 prescriptions for dermal (atopic dermatitis), inhaled (asthma) or nasal (allergic rhinitis) steroids within a 12-month period. Clustered Cox proportional hazard regression was used to estimate crude and adjusted hazard ratios (aHR) with 95% confidence intervals (95% CI).

Results

The aHR for the development of any allergic disease was 1.37 (95% CI: 1.14–1.66) for children exposed to PPIs or H2As. Prenatal exposure to PPIs and/or H2As was associated with atopic dermatitis, asthma and allergic rhinitis with aHRs of 1.32 (95% CI 1.06–1.64), 1.57 (95% CI 1.20–2.05) and 2.40 (95% CI 1.42–4.04), respectively. The aHR for the development of two or more (aHR 2.13 95% CI: 1.43–3.19) and three allergic diseases (aHR 5.18 95% CI: 2.16–12.42) were even more elevated after prenatal exposure to PPIs or H2As.

Conclusion

Prenatal exposure to PPIs and H2As appeared associated with an increased risk for the development of atopic dermatitis, asthma and allergic rhinitis in the offspring, especially with the development of multiple allergic diseases. Because our study has limitations inherent to observational studies, prospective studies are now warranted to confirm our findings.

Get access to the full text of this article

Ancillary